Chemours Co CC.N, CC is expected to show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2025
The Wilmington Delaware-based company is expected to report a 1.8% increase in revenue to $1.565 billion from $1.54 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on June 18 2025, for the period ended June 30, was for revenue between $1.56 billion and $1.59 billion.
LSEG's mean analyst estimate for Chemours Co is for earnings of 46 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Chemours Co is $15.00, about 23.3% above its last closing price of $11.50
The company's guidance on May 6 2025 for the period ended June 30 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD1.55952 billion and USD298.7 million.The company's guidance on May 6 2025 for the period ended June 30 was for Capital Expenditures of USD50 million.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.18 | 0.21 | 0.13 | Missed | -38.9 |
Dec. 31 2025 | 0.12 | 0.12 | 0.11 | Missed | -5.4 |
Sep. 30 2024 | 0.29 | 0.28 | 0.40 | Beat | 40.9 |
Jun. 30 2024 | 0.49 | 0.57 | 0.38 | Missed | -33.6 |
Mar. 31 2024 | 0.19 | 0.18 | 0.32 | Beat | 75 |
Dec. 31 2023 | 0.26 | 0.25 | 0.31 | Beat | 22.2 |
Sep. 30 2023 | 0.70 | 0.69 | 0.63 | Missed | -8.8 |
Jun. 30 2023 | 1.07 | 1.07 | 1.10 | Beat | 2.4 |
This summary was machine generated August 1 at 21:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.